Actinium Pharmaceuticals, Inc. (ATNM)

1.5800 -0.0500 (-3.07%) At close: 04:00PM EDT

Actinium Pharmaceuticals, Inc.

100 Park Avenue
23rd Floor
New York, NY 10017
United States
646 677 3870
https://www.actiniumpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 49

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Sandesh C. Seth M.B.A., M.S.	Chairman & CEO	1.21M	N/A	1964
Mr. Steven O'Loughlin BS	CFO & Corporate Secretary	590k	N/A	1986
Dr. Paul Diamond Esq., Ph.D.	Vice President of Patent & Legal Counsel	N/A	N/A	N/A
Dr. Avinash Desai M.D.	Chief Medical Officer	N/A	N/A	N/A
Ms. Jenny Hsieh	Chief Strategy Officer	N/A	N/A	N/A
Ms. Sunitha Lakshminarayanan	Senior VP, Head of CMC & Product Development	N/A	N/A	N/A
Ms. Caroline Yarbrough	Chief Commercial Officer	N/A	N/A	N/A
Ms. Lynn M. Bodarky M.B.A.	Chief Business Officer	N/A	N/A	1966
Mr. J. C. Simeon	Executive Director of Quality Assurance	N/A	N/A	N/A
Dr. Madhuri Vusirikala M.D.	Vice President of Clinical Development BMT & Cellular Therapy	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Corporate Governance

Actinium Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 1, 2024 is 10. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.